Barcelona, Spain, welcomed attendees from around the globe as they assembled in person for the European Association of Nuclear Medicine’s 35th Annual Congress.
Amidst the backdrop of distinctive architecture, a bustling city, and expansive beaches, the city of Barcelona, Spain, was this year’s host for the European Association of Nuclear Medicine’s (EANM) 35th Annual Congress. As EANM’s first onsite event since 2019, this year’s congress assembled nuclear medicine experts in person, keen to meet with colleagues from around the globe. The excitement to travel to Barcelona and gather in person was demonstrated by the participant and industry registration count that reflected pre-pandemic numbers. More than 7,000 attendees from 121 countries and over 160 business were represented at the EANM 2022 Congress.1
This year’s annual event began on Saturday, October 15, at the Centre de Convencions Internacional de Barcelona, with an opening ceremony that included a highlights lecture. The ceremony was then followed by a welcome reception.
Attendees experienced a vibrant exhibit hall showcasing the latest products and services in nuclear medicine, as well as had access to exceptional educational content, discussions, and networking events. Starting October 16, the Congress offered fourteen continuing medical education sessions throughout the four-day event. Plenary sessions on engaging topics were scheduled in the middle of each day, placed between sessions that covered a selection of wide-ranging nuclear medicine topics. Some of the key topics included theranostics/ radionuclide therapy, pediatrics, and PSMA.
PSMA as in-demand congress topic
A highlight of the congress was the Sunday plenary session, with the large auditorium filled to capacity listening to the session entitled “PSMA–A Never Ending Successful Story.” Beginning with a history of radio-labelled prostate-specific membrane antigen (PSMA) production, the 90-minute presentation featured six speakers covering an extensive range of PSMArelated content, from topics entitled “The Importance of Structured Reporting PSMA PET” to “PSMA PET in Solid Cancers Besides Prostate Cancer.” At the conclusion of the session, EANM President Stefano Fanti presented the Marie Curie award to Dr. Daniela E. Oprea Lager of the Netherlands for her PSMA research and support of implementing PSMA in guidelines.
Answering clinical needs in molecular imaging
Siemens Healthineers highlighted two products: Symbia Pro.specta™ SPECT/CT and Biograph Vision Quadra™ PET/CT. On October 18, Siemens Healthineers sponsored an industry luncheon satellite symposium entitled “Answering clinical needs in molecular imaging” and welcomed the standing-room only audience as they listened to speakers from the UK and Finland. Dr. Erin Ross, PhD, consultant clinical scientist and deputy head of nuclear medicine, and Yasmin Wahid, principal clinical technologist, both from the Queen Elizabeth Hospital Birmingham, UK, shared their insights and experiences as first users of Symbia Pro.specta. During the second half of the symposium, Professor Juhani Knuuti, MD, of the Turku PET Centre, Turku University Hospital and University of Turku, Finland, captivated the audience with a presentation on the future of PET and total-body imaging.
EANM 2022 in-person congress a success
EANM 2022 concluded on October 19, but the on-demand sessions will be available through December 20, 2022. Preparations are already underway for a yet another exciting congress scheduled to take place September 9–13, 2023, in Vienna, Austria.